Glp-1 Ra And Atrial Fibrillation In The Cardiovascular Outcome Trials

We included LEADER, SUSTAIN-6, REWIND, HARMONY, ELIXA, and PIONEER-6. While EXCSEL met our initial inclusion criteria, the incidence of atrial fibrillation was not reported as a serious adverse event. Pooled results showed no significant difference between GLP-1RA and placebo on the incidence of atrial fibrillation in individuals with type 2 diabetes (RR [95% CI] = 0.93 [0.70, 1.23], I²=58%) CONCLUSION: This review suggests that there was no significantly increased risk of incident atrial fibrillation in individuals treated with GLP-1 RAs when compared to placebo, among individuals with type 2 diabetes who either have increased cardiovascular risk or established cardiovascular disease. This article is protected by copyright. All rights reserved.